Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trial ...
Shares of Vertex, Inc. (NASDAQ:VERX – Get Free Report) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $55.52 and last traded at $55.15, with a volume of ...
Vertex Pharmaceuticals has become a leader in cystic fibrosis treatment, bringing in blockbuster revenue every year. Now, this biotech is ready to tackle a very common health problem -- and it’s ...
Let's first get the bad news for BioNTech (NASDAQ: BNTX) out of the way. BOSTON, December 08, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY ...